Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Exact Sciences Corporation    EXAS

EXACT SCIENCES CORPORATION

(EXAS)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsPress ReleasesOfficial PublicationsSector newsAnalyst Recommendations

Exact Sciences: 3Q Earnings Snapshot

10/27/2020 | 06:19am EST

MADISON, Wis. (AP) _ Exact Sciences Corp. (EXAS) on Tuesday reported a loss of $219.9 million in its third quarter.

The Madison, Wisconsin-based company said it had a loss of $1.46 per share. Losses, adjusted for asset impairment costs, were 36 cents per share.

The results exceeded Wall Street expectations. The average estimate of eight analysts surveyed by Zacks Investment Research was for a loss of 51 cents per share.

The molecular diagnostics company posted revenue of $408.4 million in the period, also beating Street forecasts. Seven analysts surveyed by Zacks expected $351 million.

Exact Sciences shares have risen 15% since the beginning of the year. The stock has increased 20% in the last 12 months.

This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on EXAS at https://www.zacks.com/ap/EXAS

Copyright by Automated Insights, Inc. All rights reserved., source Associated Press News

All news about EXACT SCIENCES CORPORATION
01/15EXACT SCIENCES CORP : Change in Directors or Principal Officers (form 8-K)
AQ
01/13EXACT SCIENCES : Licenses Targeted Digital Sequencing Method in Cancer Screening
MT
01/12EXACT SCIENCES : Oppenheimer Adjusts Price Target for Exact Sciences to $161 Fro..
MT
01/11INSIDER TRENDS : 90-Day Insider Buying Trend Reduced with Sale of Guidewire Soft..
MT
01/11SECTOR UPDATE : Narrow Rise for Most Health Care Stocks
MT
01/11EXACT SCIENCES : Projects Q4 Revenue Above Street Forecasts
MT
01/08EXACT SCIENCES : EXAS) Insider Makes Significant Share Sale
MT
01/07INSIDER TRENDS : Exact Sciences Insider Extends 90-Day Selling Trend
MT
01/05Jefferies, Exxon rise; Exact Sciences, WW International fall
AQ
01/05EXACT SCIENCES : Sees Q4 Revenue To Exceed Market Expectations
MT
More news
Financials (USD)
Sales 2020 1 465 M - -
Net income 2020 -396 M - -
Net cash 2020 182 M - -
P/E ratio 2020 -54,1x
Yield 2020 -
Capitalization 23 668 M 23 668 M -
EV / Sales 2020 16,0x
EV / Sales 2021 12,9x
Nbr of Employees 4 110
Free-Float 99,1%
Chart EXACT SCIENCES CORPORATION
Duration : Period :
Exact Sciences Corporation Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends EXACT SCIENCES CORPORATION
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 16
Average target price 149,33 $
Last Close Price 148,83 $
Spread / Highest target 10,9%
Spread / Average Target 0,34%
Spread / Lowest Target -48,9%
EPS Revisions
Managers and Directors
NameTitle
Kevin T. Conroy Chairman, President & Chief Executive Officer
Ana Hooker Senior Vice President-Operations
Jeffrey Thomas Elliott Chief Financial Officer
Graham Peter Lidgard Chief Science Officer, SVP-Research & Development
Sandra Statz SVP-Clinical & Regulatory Affairs
Sector and Competitors
1st jan.Capitalization (M$)
EXACT SCIENCES CORPORATION12.33%23 668
GUARDANT HEALTH, INC.24.10%15 990
INVITAE CORPORATION33.60%9 870
ADAPTIVE BIOTECHNOLOGIES CORPORATION13.88%9 210
BGI GENOMICS CO., LTD.17.29%9 087
IOVANCE BIOTHERAPEUTICS, INC.9.76%7 471